Bladder Cancer Treatment Denied by Insurance: How to Appeal

Bladder cancer is one of the most common cancers in the United States, with non-muscle-invasive bladder cancer (NMIBC) making up the majority of diagnoses. BCG (Bacillus Calmette-Guérin) intravesical immunotherapy is a cornerstone of NMIBC treatment — but nationwide BCG shortages have forced patients and oncologists to seek alternative treatments, which insurers frequently deny. For muscle-invasive and metastatic bladder cancer, pembrolizumab, cisplatin-based chemotherapy, and radical cystectomy are standard treatments that also face denial. This guide explains your rights and how to appeal.

BCG Shortage and Alternative Treatments

BCG intravesical therapy is FDA-approved for high-risk NMIBC — high-grade tumors, CIS (carcinoma in situ), and T1 disease. The ongoing shortage of BCG has forced urologists to consider alternatives including:

• Gemcitabine intravesical therapy: NCCN-recommended alternative for BCG-intolerant or BCG-unavailable patients
• Mitomycin C: Established intravesical agent, particularly for intermediate-risk NMIBC
• Nadofaragene firadenovec (Adstiladrin): FDA-approved intravesical gene therapy for BCG-unresponsive, high-risk NMIBC
• Pembrolizumab (Keytruda): FDA-approved for BCG-unresponsive CIS with papillary tumors

Insurers frequently deny these BCG alternatives by:

• Requiring documentation of BCG unavailability (which the treating urologist should provide)
• Calling nadofaragene or pembrolizumab "investigational" despite FDA approval for the specific BCG-unresponsive indication
• Denying intravesical gemcitabine or mitomycin as "not medically necessary" when BCG is temporarily unavailable

Pembrolizumab for Advanced Bladder Cancer

Pembrolizumab is FDA-approved for locally advanced or metastatic urothelial carcinoma (UC) following platinum-based chemotherapy, and as first-line therapy for patients who are not eligible for cisplatin and have PD-L1-positive tumors. Enfortumab vedotin (Padcev) in combination with pembrolizumab received accelerated FDA approval for first-line metastatic UC, including cisplatin-ineligible patients.

Insurers deny these treatments by:

• Applying incorrect PD-L1 cutoffs or test types (CPS vs. IC scoring)
• Requiring cisplatin-based chemotherapy first even when the patient is cisplatin-ineligible
• Denying the enfortumab vedotin + pembrolizumab combination as "investigational" despite accelerated approval

Radical Cystectomy Authorization

Radical cystectomy — surgical removal of the bladder — is the standard treatment for muscle-invasive bladder cancer (MIBC) in patients eligible for surgery. Insurers may deny:

• Authorization for radical cystectomy itself, calling it "elective" — which is not supportable for MIBC
• Neoadjuvant cisplatin-based chemotherapy (MVAC, ddMVAC, or gemcitabine/cisplatin) before cystectomy, which is NCCN Category 1 and reduces recurrence risk
• Robotic-assisted laparoscopic radical cystectomy, requiring open surgery instead
• Urinary diversion reconstruction (ileal conduit, orthotopic neobladder) as a "separate" service not covered

NMIBC Surveillance

Following NMIBC treatment, cystoscopy and urine cytology surveillance are standard per AUA and NCCN guidelines. For high-risk NMIBC, cystoscopy every 3 months for 2 years, then every 6 months for 2 years, then annually is standard. Insurers may limit surveillance cystoscopy frequency as "excessive."

Your Legal Rights

ACA protections: Bladder cancer treatment is covered under essential health benefits with no annual or lifetime dollar limits.

FDA approval documentation: For nadofaragene and pembrolizumab in BCG-unresponsive NMIBC, FDA approval letters and prescribing information directly address the "investigational" denial argument.

External Independent Review: Complete Guide" class="auto-link">External review: Independent review by a board-certified urologist or urologic oncologist regularly overturns denials for BCG alternatives and cystectomy authorization.

Expedited appeals: For patients with high-grade NMIBC or MIBC at risk of progression, expedited review (72 hours) is clinically warranted.

Building Your Appeal

1. Cystoscopy and biopsy reports: Confirming NMIBC grade/stage (Ta, T1, CIS) or MIBC
2. BCG treatment history and shortage documentation: Prior BCG use, documented unavailability from pharmacy/urologist
3. NCCN Bladder Cancer Guidelines: Cite specific alternative treatment recommendations for BCG-unresponsive disease
4. FDA prescribing information: For nadofaragene or pembrolizumab in BCG-unresponsive NMIBC
5. Letter of medical necessity: From the treating urologist or urologic oncologist
6. PD-L1 testing result: If pembrolizumab is denied for urothelial carcinoma

Fight Back With ClaimBack

ClaimBack helps bladder cancer patients navigate insurance denials for BCG alternatives, pembrolizumab, cystectomy, and surveillance. Our platform provides the structure to build an appeal that insurers cannot easily dismiss.

Start your appeal at ClaimBack

Bladder cancer insurance denials — whether for BCG alternatives or surgery — are reversible. A complete, well-documented appeal is your most effective tool.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied